---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-008617"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2025-03-21T23:59:59+00:00"
generated_at: "2026-05-24T09:26:14.338245+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vaxart reports FY2024 net loss $66.9M, revenue $28.7M; initiates Phase 1 norovirus trial

## Summary
- Net loss $66.9M ($0.33/sh) vs $82.5M in 2023; revenue $28.7M (up from $7.4M).
- Cash $51.7M provides runway into Q4 2025; workforce reduced ~10% after COVID trial stop-work order.
- Phase 1 trial of second-gen norovirus vaccine started; topline data expected mid-2025.
- COVID-19 Phase 2b sentinel cohort enrolled; U.S. government stop-work order issued, only per-protocol follow-up allowed.

## SEC filing metadata
- accession: 0001437749-25-008617
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2025-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774925008617/0001437749-25-008617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774925008617/vxrt20250320_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-008617
- JSON: https://secwatch.observer/filing/0001437749-25-008617.json
- Plain text: https://secwatch.observer/filing/0001437749-25-008617.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.